These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 32860011)

  • 1. Abiraterone and enzalutamide had different adverse effects on the cardiovascular system: a systematic review with pairwise and network meta-analyses.
    Lee HY; Chen HL; Teoh JY; Chen TC; Hao SY; Tsai HY; Huang WH; Juan YS; Cheng HM; Chang HM
    Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):244-252. PubMed ID: 32860011
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of effectiveness and safety outcomes of abiraterone versus enzalutamide in patients with metastatic castration-resistant prostate cancer: a systematic review and meta-analysis.
    Wang X; Hui Y; Wang S; Hu X; Yu X; Wang W; Zhang X; Liu L
    J Pharm Pharm Sci; 2020; 23():451-461. PubMed ID: 33217255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the clinical efficacy and safety of abiraterone and enzalutamide in metastatic castration-resistant prostate cancer: A systematic review and meta-analysis.
    Wang X; Yang H; Hu X; Wang W; Yu X; Wang S; Zhang X; Liu L
    J Oncol Pharm Pract; 2021 Apr; 27(3):614-622. PubMed ID: 32529950
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.
    Iacovelli R; Ciccarese C; Bria E; Romano M; Fantinel E; Bimbatti D; Muraglia A; Porcaro AB; Siracusano S; Brunelli M; Mazzarotto R; Artibani W; Tortora G
    Clin Genitourin Cancer; 2018 Jun; 16(3):e645-e653. PubMed ID: 29339044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality of life in men with metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone: a systematic review and meta-analysis.
    Ternov KK; Nolsøe AB; Bratt O; Fode M; Lindberg H; Kistorp C; Palapattu G; Klausen TW; Sønksen J; Østergren PB
    Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):948-961. PubMed ID: 33820951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of Chemotherapy, Enzalutamide, Abiraterone, and Radium 223 With Cognitive Function in Older Men With Metastatic Castration-Resistant Prostate Cancer.
    Alibhai SMH; Breunis H; Feng G; Timilshina N; Hansen A; Warde P; Gregg R; Joshua A; Fleshner N; Tomlinson G; Emmenegger U
    JAMA Netw Open; 2021 Jul; 4(7):e2114694. PubMed ID: 34213559
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness of first-line abiraterone versus enzalutamide among patients ≥80 years of age with metastatic castration-resistant prostate cancer: A retrospective propensity score-weighted comparative cohort study.
    Soleimani M; Zou K; Sunderland K; Struss W; Eigl BJ; Nappi L; Kollmannsberger CK; Finch D; Noonan K; Vergidis J; Zulfiqar M; Chi KN; Khalaf DJ
    Eur J Cancer; 2021 Jul; 152():215-222. PubMed ID: 34130153
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.
    Bianchini D; Lorente D; Rodriguez-Vida A; Omlin A; Pezaro C; Ferraldeschi R; Zivi A; Attard G; Chowdhury S; de Bono JS
    Eur J Cancer; 2014 Jan; 50(1):78-84. PubMed ID: 24074764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and tolerability of targeted drugs for the treatment of metastatic castration-resistant prostate cancer: a network meta-analysis of randomized controlled trials.
    Wang Y; Zhang H; Shen W; He P; Zhou Z
    J Cancer Res Clin Oncol; 2018 Sep; 144(9):1751-1768. PubMed ID: 29797220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of Metabolic and Cardiovascular Adverse Events With Abiraterone or Enzalutamide Among Men With Advanced Prostate Cancer.
    Lai LY; Oerline MK; Caram MEV; Tsao PA; Kaufman SR; Hollenbeck BK; Shahinian VB
    J Natl Cancer Inst; 2022 Aug; 114(8):1127-1134. PubMed ID: 35417024
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.
    Armstrong AJ; Lin P; Tombal B; Saad F; Higano CS; Joshua AM; Parli T; Rosbrook B; van Os S; Beer TM
    Eur Urol; 2020 Sep; 78(3):347-357. PubMed ID: 32527692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of abiraterone and enzalutamide for castration-resistant prostate cancer: A systematic review and meta-analysis of randomized controlled trials.
    Zheng X; Zhao X; Xu H; Han X; Xu H; Dong X; Peng R; Yang L; Wei Q; Ai J
    Medicine (Baltimore); 2019 Nov; 98(44):e17748. PubMed ID: 31689828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hospitalization for adverse events under abiraterone or enzalutamide exposure in real-world setting: A French population-based study on prostate cancer patients.
    Scailteux LM; Despas F; Balusson F; Campillo-Gimenez B; Mathieu R; Vincendeau S; Happe A; Nowak E; Kerbrat S; Oger E
    Br J Clin Pharmacol; 2022 Jan; 88(1):336-346. PubMed ID: 34224605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.
    Kumar J; Jazayeri SB; Gautam S; Norez D; Alam MU; Tanneru K; Bazargani S; Costa J; Bandyk M; Ganapathi HP; Koochekpour S; Balaji KC
    Urol Oncol; 2020 Nov; 38(11):826-834. PubMed ID: 32605736
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Circulating Tumor Cell Chromosomal Instability and Neuroendocrine Phenotype by Immunomorphology and Poor Outcomes in Men with mCRPC Treated with Abiraterone or Enzalutamide.
    Brown LC; Halabi S; Schonhoft JD; Yang Q; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Barnett ES; Carbone EA; Zhao JL; Healy P; Anand M; Gill A; Jendrisak A; Berry WR; Gupta S; Gregory SG; Wenstrup R; Antonarakis ES; George DJ; Scher HI; Armstrong AJ
    Clin Cancer Res; 2021 Jul; 27(14):4077-4088. PubMed ID: 33820782
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis.
    Brasso K; Thomsen FB; Schrader AJ; Schmid SC; Lorente D; Retz M; Merseburger AS; von Klot CA; Boegemann M; de Bono J
    Eur Urol; 2015 Aug; 68(2):317-24. PubMed ID: 25108579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Clinical efficacy and safety of enzalutamide in metastatic castration-resistant prostate cancer: systematic review and meta-analysis].
    Brodszky V; Péntek M; Baji P; Rencz F; Géczi L; Szûcs M; Berczi C; Gulácsi L
    Magy Onkol; 2014 Sep; 58(3):189-97. PubMed ID: 25260083
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
    Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
    Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of major adverse cardiovascular events among second-line hormonal therapy for metastatic castration-resistant prostate cancer: A real-world evidence study.
    Liu JM; Lin CC; Chen MF; Liu KL; Lin CF; Chen TH; Wu CT
    Prostate; 2021 Feb; 81(3):194-201. PubMed ID: 33393676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.